# Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

> **NCT03941093** · PHASE3 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 284 (actual)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **DRUG:** Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
- **DRUG:** Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

## Key facts

- **NCT ID:** NCT03941093
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-10
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941093, "Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT03941093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*